Markers of inflammation and coronary artery disease

Medical Science Monitor

Volumn 8, Issue 1, 2002, Pages

  Saadeddin, Salam M ^a   Habbab, MoH'D A ^b   Ferns, Gordon A ^c  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c PRINCE SULTAN CARDIAC CENTER   (Saudi Arabia)

Author keywords

Acute phase proteins; Adhesion molecules; Coronary artery disease; Cytokines; Inflammation

Indexed keywords

CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; INFLAMMATION; REVIEW; RISK ASSESSMENT;

ACUTE-PHASE PROTEINS; APOLIPOPROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; CORONARY ARTERIOSCLEROSIS; CYTOKINES; FIBRINOGEN; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; SERUM AMYLOID A PROTEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036164830     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. Inflammation and coronary artery disease
2. Atherosclerosis: An inflammatory disease
3. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease
4. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
5. Inflammation of the coronary arteries in patients with unstable angina
6. Human lesion studies
7. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association
8. Inflammation, the endothelium and acute coronary syndromes
9. Endothelium and acute coronary syndromes
10. The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment
11. Novel inflammatory markers of coronary risk. Theory versus practice
12. Adhesion of human basophils, eosinophils, and neutrophils to interleukin-I activated endothelial cells: Contributions of endothelial cell adhesion molecules
13. Leukocyte-endothelial adhesion molecules
14. Adhesion molecules
15. Soluble vascular cell adhesion molecule-I as a biohumoral correlate of atherosclerosis
16. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atheroselerosis Risk in Communities (ARIC) study
17. Interleukin-6: The major regulator of acute-phase protein synthesis in man and rat
18. Acutc-phase proteins and other systemic responses to inflammation
19. Biological basis for interleukin-I in disease
20. The role of interleukin-I in disease
21. CDNA expression cloning of the II.-I receptor, a member of the immunoglobulin superfamily
22. Two high affinity interleukinI receptors represent separate gene products
23. Molecular cloning and characterization of a second subunit of the interleukin-I receptor complex
24. The type II 'decoy' receptor: A novel regulatory pathway for interleukin-1
25. Induction of interleukin-I expression in human vascular smooth muscle cells
26. Endotoxin and tumor necrosis factor induce interleukin-I gene expression in adult human vascular endothelial cells
27. Interleukin I induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells
28. Interactions between bacterial liposaccharides and serum lipoproteins and their possible role in coronary artery disease
29. Interleukin-1β in coronary arteries of patients with ischemic heart disease
30. Production of tumor necrosis factor and interlenkin-1 by macrophages from human atheromatous plaques
31. Increased serum concentrations of interleukin-1β in patients with coronary artery discase
32. Increasing levels of interleukin (1L) 1 Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
33. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease
34. Tumor necrosis factor: Function, release and clearance
35. Elevated cerculating levels of tumor necrosis factor in severe chronic heart failure
36. Two TNF receptors
37. The two different receptors for tumor necrosis factor mediate distinct cellular responses
38. Multifunctional regulation of the biological effects of TNF-(by the soluble type I and type II TNF receptors
39. Interleukin-I necrosis factor and their specif]ic inhibitors
40. Detection and localization of TNF in human atheroma
41. Circulating tumor necrosis factor-α (cachcctin) in myocardial infarction
42. Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction
43. The acute phase response
44. Role of cytokines in inducing hyperlipidemia
45. Adipose expression of tumor necrosis factor alpha: Direct role in obesity linked insulin resistance
46. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance
47. Interleukin-6
48. Soluble cytokine receptors: Their roles in immunoregulation, disease, and therapy
49. Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo
50. Soluble forms of the interleukin-6 signal-transducing receptor component gp 130 in human serum possessing a potential to inhibit signals through membraneanchored gp 130
51. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6
52. Platelet activation induced by interleukin-6: Evidence for a mechanism involving arachadunic acid metabolism Thromb Haemost
53. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons
54. Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
55. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans
56. Interleukin-6 stimulates the growth of vascular cells in a PDGF dependent manner
57. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall
58. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease
59. Mortality risk associated with elevated interleukin-6 and C-reactive protein in old age
60. Elevated levels of 1L-6 in unstable angina
61. Elevated levels of C-reactive protein at discharge predicts recurrent instability in patients with unstable angina
62. Increasing levels of interleukin (1L)-1 Ra and IL,6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
63. Chemokines and leukocyte traffic
64. Chemokines, receptors, and their role in cardiovascular pathology
65. Chemokines-chemolactic cytokines that mediate inflammation
66. Human chemokines: An update
67. Chemokines: Leukocyte recruitment and activation cytokines
68. Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions
69. Neutrophil-activating peptideI/interleukin 8, a novel cytokine that attracts neutrophils
70. Monocytc chemoattractant protein-I in human atheromatous plaques
71. Expression of monocyte chemoattractant protein in macrophage-rich areas of human and rabbit atherosclerotic lesions
72. Detection of monocyte chemoattractant protein-I in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-I monoclonal antibody
73. Interleukin-8 production by macrophages from atheromatous plaques
74. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma
75. Actions of the chemotactic cytokines MCP-I, MCP-2, MCP-3, RANTES, MIP-1α and MIP-1β on human monocytes
76. Monocyte chemotactic protein-I (MCP-1),-1 and -3 are chemotactic for human T lymphocytes
77. Modulation of IL-8 receptor expression on purified human T lymphocytes is associated with changed chemotactic responses to IL-8
78. MCP-1 and IL-8 trigger firm adhesion of mouocytes to vascular endotheliurn under flow conditions
79. Interleukin-8 as a macrophage-derived mediator of angiogenesis
80. Interleukin-8: A mitogen and chemoattractant for vascular smooth muscle cells
81. Site of intimal rupture or erosion of thrombosal coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
82. Cell-mediated immunity in atherosclerosis
83. Endothelial-dependent mechanisms of mononuclear leukocyte recruitment
84. Traffic signals on endothelium for lymphocyte rccirculation and leukocyte emigration
85. Cell adhesion molecules in coronary arlery disease
86. Circulating endothelial cell/lcukocyte adhesion molecules in atherosclerosis
87. Prospective study of hemostatic factors and incidence of coronary heart disease
88. Comparison of the prediction by 27 different risk factors ofcoronary heart disease and death in men and women of the Scottish Heart Health Study
89. Acute myocardial infarction and increased soluble intercellular adhesion molecule-1: A marker of vascular inflammation and a risk of early rcstcnosis
90. Alterations in circularing intercellular adhesion molecule-1 and L-selectin: Further evidence for chronic inflammation in ischemic heart disease
91. Elevated levels of circulating soluble adhesion molecules in peripheral blood of patients with unstable angina
92. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease
93. Plasma soluble intercellular adhesion molecule-1 levels in coronary circulation in patients with unstable angina
94. C-reactive protein: Fifty years on
95. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction
96. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
97. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
98. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein
99. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
100. The prognostic value of C-reaclive protein and serum amyloid a protein in severe unstable angina
101. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain
102. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
103. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction
104. Independent prognostic value of elevated C-reactive protein in unstable angina
105. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin 'I' in acute coronary syndromes: A TIMI 11A substudy
106. Production of C-reactive protein and risk of coronary events in stable and unstable augina
107. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
108. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial
109. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
110. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women (see comments)
111. Relationship of C-reactive protein to risk ofcardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
112. Infections, inflammation, and the risk of coronary heart disease
113. Phisma concentration of C-reactive protein and risk of developing peripheral vascular disease
114. Low grade inflammation and coronary heart disease: Prospective study and updated metaanalyses
115. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men
116. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
117. Long-term effects of pravastatin on plasma concentration of C-reactive protein
118. Immunologic studies of the major nonimmunoglobulin protein of amyloid: Identification and partial characterization of a related serum component
119. Serum amyloid A in acute phase protein and apolipoprotein
120. Amyloid: Extraction and preliminary characterization of some proteins
121. Human serum amyloid A (SAA) protein: A prominent acute-phase reactant for clinical practice
122. Serum amyloid A (SAA): Influence on HDL-mediated cellular cholesterol efflux
123. Biosynthesis of human acute-phase serum amyloid A protein (A-SAA) in vitro: The roles of mRNA accumulation, poly (A) tail shortening and translational effidency
124. IL-1 receptor antagonist (IL-IRa) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumor cells
125. Widespread expression of serum amyloid A in histological normal human tissues: Predominant localization to the epithelium
126. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function
127. Human serum amyloid A genes are present in monocyte/macrophage cell lines
128. Both acute phase and constitutive serum amyloid A are present in atherosclerofic lesions
129. Serum amyloid A changes high density lipoprotein's cellular affinity: A clue to serum amyloid's principal function
130. Serum amyloid A-containing human high density lipoprotein 3: Density, size and apolipoprotein composition
131. Influeace of serum amyloid A on cholesterol esterification in human plasma
132. 2microglubulin-like proteins
133. Serum amyloid A protein induces production of matrix matalloproteinases by human synovial fibroblasts
134. The effect of serum amyloid protein A fragment-SAA25-76 on blood platelet aggregation
135. Serum amyloid A, an acute phase protein, inhibits platelet activation
136. Modulation of prostaglandin 12 production from bovine aortic endothelial cells by serum amyloid A and its N-terminal tetradecapeptide
137. Atherosclerosis: Basic mechanism-oxidation, inflammation and genetics
138. Serum amyloid A predicts early mortality in acute coronary syndromes. A TIMI I1A substudy
139. Fibrinolytic activation markers predict myocardial infarction in the elderly: The Cardiovascular Health Study
140. Production of C-reactive protein and risk of coronary events in stable and unstable angina
141. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
142. Cardiovascular risk factors and hemorheology. Physical fitness, stress and obesity
143. The possible role of hemorheology in atherothrombogenesis
144. Fibrinogen as a cardiovascular risk factor
145. Elevated plasma inlerleukin-6 levels in patients with acute myocardial infarction
146. Atherosclerosis and the coagrtfiation system
147. Fte kof fibrinogen in human arterial intima
148. Hematological stress syndrome in atherosclerosis
149. White blood cell count and cardiovascular disease. Insights from the Framingham Study
150. Prospective study of hemostatic factors and incidence of coronary heart disease
151. Prognostic value of plasnm fibrinogen concentration in patients with unstable angina and non-Q wave infarction enrolled in the TIMI 111 trial
152. Fibrinogen and factor VIII, but no factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: Results from the Cardiovascular Health Study